TABLE 2.
Enrollment Demographic and Clinical Characteristics by Prescriber Type
| Characteristic | Specialist† (n = 6,925) | General Practitioner (n = 2,558) | Other † (n = 1,340) |
|---|---|---|---|
| Cirrhosis ‡ | |||
| Yes | 1,853 (27) | 251 (10) | 246 (18) |
| No | 5,053 (73) | 2,281 (89) | 1,088 (81) |
| Unknown | 19 (<1) | 26 (1) | 6 (<1) |
| Prescribed therapy | |||
| SOF/LDV | 2,693 (39) | 1,023 (40) | 496 (37) |
| SOF/DCV | 2,064 (30) | 619 (24) | 375 (28) |
| SOF+RBV | 167 (2) | 38 (1) | 17 (1) |
| PrOD | 82 (1) | 16 (1) | 13 (1) |
| GRZ/ELB | 277 (4) | 95 (4) | 80 (6) |
| GRZ/ELB+SOF | 11 (<1) | 0 (0) | 0 (0) |
| SOF/VEL | 1,365 (20) | 633 (25) | 253 (19) |
| SOF/VEL/VOX | 16 (<1) | 6 (<1) | 4 (<1) |
| GLE/PIB | 227 (3) | 105 (4) | 101 (8) |
| Prescribed treatment duration | |||
| 8 weeks | 637 (9) | 542 (21) | 254 (19) |
| 12 weeks | 5,246 (76) | 1,898 (74) | 972 (73) |
| 16 weeks | 15 (<1) | 0 (0) | 5 (<1) |
| 24 weeks | 1,014 (15) | 96 (4) | 106 (8) |
Data are presented as n (%).
*
Gastroenterologist, hepatologist, or infectious disease physician.
†
Sexual health physician, general physician, mental health practitioner, nurse practitioner, or other.
‡
Determined by any method.
Abbreviations: DCV, daclatasvir; ELB, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; PIB, pibrentasvir; PrOD, paritaprevir/ritonavir/ombitasvir + dasabuvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir.